apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain.

By R. Deane, A. Sagare, Katie Hamm, Margaret Parisi, Steven M. Lane, M. Finn, D. Holtzman, Berislav Zlokovic. Journal of Clinical Investigation, 2008

780 citations recorded by the source corpus.

Subfields: Neurology, Oncology, Physiology

View Paper: https://www.semanticscholar.org/paper/4468d75e38c4b30956ce43ab2226294c32de8966

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

1. Berislav Zlokovic
2. D. Holtzman
3. R. Bell
4. Maiken Nedergaard
5. John C. Morris
6. A. Goate
7. G. Bu
8. C. Iadecola

In Oncology

1. Berislav Zlokovic
2. G. Bu
3. D. Holtzman
4. R. Bell

In Physiology

1. D. Holtzman
2. Berislav Zlokovic
3. A. Goate
4. G. Bu
5. J. Herz
6. R. Bell
7. John C. Morris
8. Maiken Nedergaard

Citations in the corpus

• The Glymphatic System – A Beginner's Guide (2015, positive): “Bulk clearance by the glymphatic system might in combination with transport across the blood-brain barrier [59] provide necessary and sufficient removal of extracellular β-amyloid until the end of the reproductive lifespan around which time failure in adequate CSF bulk flow leads to accumulation of ”
• Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease (2009, background): “ApoE has been associated with impaired transport of Ab across the BBB [9, 24, 58].”
• Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. (2012, background): “Interestingly, a recent study shows that Ab binding to apoE4 redirects its clearance from LRP1 to VLDLR, which internalizes Ab-apoE4 complexes at the BBB more slowly than LRP1 (Deane et al. 2008).”